A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine
Latest Information Update: 01 Sep 2025
At a glance
- Drugs MEDI 0618 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms AURORA
- Sponsors AbbVie; AstraZeneca
Most Recent Events
- 08 Apr 2025 Planned End Date changed from 7 Sep 2026 to 15 Sep 2025.
- 08 Apr 2025 Planned primary completion date changed from 7 Sep 2026 to 15 Sep 2025.
- 08 Apr 2025 Status changed from recruiting to active, no longer recruiting.